This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Shares of Canadian cannabis giant Canopy Growth surged after the company reported Q3 earnings Wednesday morning, with shares up more than 15 percent at the close of the day's trading session. Despite net revenue declining year-over-year, Canopy beat analyst expectations and has ramped up efforts to develop a "THC ecosystem' in the U.S. Canopy Growth's CEO, David Klein, joined Cheddar News' Closing Bell to discuss the report. He noted that its brands Storz & Bickel vaporizers and BioSteel beverages showed record growth.
The Central Park Conservancy announced last month it has partnered with the Yale School of the Environment and the New York City-based Natural Areas Conservancy to study the on-the-ground impacts of climate change on urban parks. Salmaan Khan, Director of Research and Special Projects at the Central Park Conservancy joins Cheddar Climate to explain what factors put this initiative into motion and what data his team will be looking to uncover.
Energy Impact Partners is a VC firm committed to helping the world move toward a more sustainable future. The tech-focused fund aims to reach $350 million for its Deep Decarbonization Frontier Fund,' which aims to support early-stage companies working on innovative solutions. Energy Impact Partners' Managing Director Andy Lubershane joined Cheddar Climate to discuss.
Mukul Bakhshi, Chief of Strategy and Government Affairs for CGFNS International, joins Cheddar News to discuss strained U.S. hospitals seeking foreign nurses.
The Democratic governors of New Jersey, Connecticut, Delaware, and Oregon say they will lift mask requirements for schools in the coming weeks, reflecting a nationwide shift away from restrictions. Cheddar News speaks with internist Dr. Vivek Cherian whether it's safe to relax the regulation.
After months of investigation, board members from U.S. big oil companies were slated to appear before a House oversight committee this week to discuss their respective roles in pushing for climate initiatives internally. However, all four board members from Exxon, Shell, Chevron, and BP said they couldn't attend due to scheduling conflicts. Climate experts are testifying in their place about how effective big oil's climate promises have been so far. Meanwhile, President Joe Biden's lead science adviser Eric Lander has resigned after an investigation found he violated workplace policy. What will this mean for Biden's climate agenda? Amy Harder, executive editor of Cipher, a publication by Breakthrough Energy, joins Cheddar Climate to discuss.
Although this week's weather is predicted to be less severe than the 2021 storm, Texans are preparing for the worst - stocking up on supplies and emptying shelves in grocery stores, once again. Some Texans still have not recovered from last year's tragedy, and are heading into the next few weeks with anxiety for what's to come. Leslie Beyer, CEO of the Houston-based energy workforce & technology council, joins Cheddar News to discuss if the Texas grid will fail again.
The American Red Cross has declared its first-ever "national blood crisis" in the United States. Since COVID hit the U.S. in March 2020, blood donations have declined by 10 percent. American Red Cross Medical Director, Dr. Baia Lasky joined Cheddar News to discuss the country facing the worst blood shortage in over a decade. Dr. Lasky noted that as much as 40 percent of Americans are eligible to donate blood but only about 4 percent do so. "This is going to be ongoing," she said. "This is not an acute shortage. We really do need the commitment of people to come out and donate and donate again." Appointments to donate can be made by using the Red Cross Donor App, at RedCrossBlood.org, or calling 1-800-RED CROSS (1-800-733-2767).
Eight months after the National Football League announced $1 million in research into cannabinoids, the NFL-NFLPA Joint Pain Management Committee has awarded the funding to two teams of medical researchers at the University of California San Diego and the University of Regina. The NFL says the studies will investigate the effects of cannabinoids on pain management and neuroprotection from concussion in elite football players, respectively. Cheddar correspondent Chloe Ailello spoke with Jeff Miller, the executive vice president of communications, public affairs, and policy for the NFL, about the studies, as well as the recent lawsuit filed against the NFL by former Miami Dolphins head coach Brian Flores. "Maybe we can learn things from other alternative pain approaches that are going to benefit our player population and then sports medicine as a whole," Miller said.
On this episode of Cheddar Innovates: CEO of HereAfter AI discusses how artificial intelligence can be used to preserve family history and stories, and allow you to 'talk' to loved ones that have passed; Creator of the board game 'Travel Explore Discover' explains how she came up with the idea for this informative and educational board game, and how she's using the proceeds to give back to her community; Cheddar gets a look at Curiosity Stream's 'The Humboldt Current.'
